Mesoblast Financial Results 2016 Annual Report

Mesoblast's financial results presentation for the fiscal year ended 30 June 2016, covering technology review, operational updates, and timelines. The deck includes forward-looking statements regarding stem cell technology development, regulatory approvals, manufacturing scalability, and strategic partnerships with JCR Pharmaceuticals and Lonza.